Antivirale Therapie bei Patienten mit chronischer Hepatitis C ... - DIMDI

Antivirale Therapie bei chronischer Hepatitis C.
222. Stark K, Muller R, Bienzle U, Guggenmoos-Holzmann I: Frontloading: a risk factor for HIV
and hepatitis C virus infection among injecting drug users in Berlin. In: Aids 10 (1996) 3,
S. 311-317.
223. Stark K, Schreier E, Muller R, Wirth D, Driesel G, Bienzle U: Prevalence and determinants
of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin.
In: Scand J Infect Dis 27 (1995) 4, S. 331-337.
224. Statistisches Bundesamt Deutschland: Durchschnittliche weitere Lebenserwartung 1999:
http://www.destatis.de/basis/d/bevoe/bevoetab3.htm (31.12.2002).
225. Statistisches Bundesamt Deutschland: Preisindex für Arzt-, Krankenhaus- und sonstige
Dienstleistungen für die Gesundheitspflege. 2000:
http://www.destatis.de/indicators/d/vpi002aj.htm (31.12.2002).
226. Steimann R, Bode J: [Does combination therapy of chronic viral hepatitis C with
interferon-alpha and ribavirin approach financial limits?]. In: Versicherungsmedizin 52
(2000) 1, S. 24-27.
227. Steimann R, Bode J: [Does combination therapy of chronic viral hepatitis C with
interferon-alpha and ribavirin approach financial limits?]. In: Versicherungsmedizin 52
(2000) 1, S. 24-27.
228. Stein K, Rosenberg W, Wong J: Cost effectiveness of combination therapy for hepatitis C:
a decision analytic model. In: Gut 50 (2002) 2, S. 253-258.
229. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T: Natural course of chronic
hepatitis C. In: Am J Gastroenterol 88 (1993) 2, S. 240-243.
230. Taylor-Robinson S, Foster G, Arora S, Hargreaves S, Thomas H: Increase in primary liver
cancer in the UK, 1979-94. In: Lancet 350 (1997) 9085, S. 1142-1143.
231. Tong M, Blatt L, McHutchison J, Co R, Conrad A: Prediction of response during interferon
alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics:
a comparison. In: Hepatology 26 (1997) 6, S. 1640-1645.
232. Tong M, Blatt L, Resser K, Klein M, Cruickshank S, Figueroa T, Sayadzadeh K:
Treatment of chronic hepatitis C virus infection with recombinant consensus interferon. In:
Journal of Interferon & Cytokine Research 18 (1998) 2, S. 81-86.
233. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero M, Realdi G: Long-term
follow-up of non-A, non-B (type C) post-transfusion hepatitis. In: J Hepatol 16 (1992), S.
273-281.
234. Trepo C, Lindsay K, Niederau C, Schiffman M, Gordon S, Hoefs J, Schiff E, Marcellin P,
Bacon B, Fang J, Garaud J, Albrecht J, for the Hepatitis Intervention Therapy Group:
Pegylated interferon alfa-2B (Peg-Intron) monotherapy is superior to interferon alfa-2B
(Intron A) for the treatment of chronic hepatitis C. In: J Hepatol 32 (2000) Suppl. 2, S.
A29.
235. Verbaan HP, Widell HE, Bondeson TL, Lindgren SC, Swedish HCVTG: High sustained
response rate in patients with histologically mild (low grade and stage) chronic hepatitis C
infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with
and without ribavirin.[comment]. In: European Journal of Gastroenterology & Hepatology
14 (2002) 6, S. 627-633.
236. Ware J, Jr, Bayliss M, Mannocchia M, Davis G: Health-related quality of life in chronic
hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.
In: Hepatology 30 (1999) 2, S. 550-555.
DAHTA@DIMDI 107